Causes and Risk Factors

The side effects stem from the beta radiation emitted by ^90Y microspheres and the physical embolic effect of the beads blocking small arterial vessels.

Primary Causes

• Radiation dose to non‑target tissue – Mis‑placement of microspheres can expose healthy liver, stomach, pancreas, or lungs.
• Ischemia from embolization – Blocking arterial flow can cause temporary hypoxia of liver tissue.
• Inflammatory response – The body’s reaction to foreign particles produces cytokines that contribute to fatigue, fever, and pain.

Key Risk Factors

• Pre‑existing liver disease – Cirrhosis, hepatitis B/C, or non‑alcoholic steatohepatitis increase susceptibility to RILD.
• High lung shunt fraction – Measured on technetium‑99m macroaggregated albumin (MAA) scan; >20 % raises lung dose.
• Large tumor burden – Involvement of >50 % of liver volume correlates with higher toxicity.
• Prior liver radiation or chemo‑embolization – Cumulative damage escalates risk.
• Poor performance status (ECOG ≥3) – Limits physiologic reserve to handle inflammation.
• Age >75 years – Older patients may have reduced hepatic regeneration capacity.

Diagnosis

Diagnosing side effects involves a combination of clinical assessment, laboratory testing, and imaging.

Clinical Evaluation

• Detailed history focusing on timing, severity, and pattern of symptoms.
• Physical exam: abdomen (tenderness, ascites), skin (injection‑site changes), respiratory exam (if pneumonitis suspected).

Laboratory Tests

• Complete blood count (CBC) – to detect leukopenia or thrombocytopenia.
• Liver panel (ALT, AST, ALP, GGT, bilirubin, albumin) – monitor hepatic injury.
• Coagulation profile (INR, PT) – important if liver synthetic function declines.
• Renal function (creatinine, BUN) – especially before using contrast in imaging.

Imaging Studies

• Contrast‑enhanced CT or MRI – evaluates for tumor response, new lesions, or radiation‑induced changes (e.g., edema, capsular retraction).
• Ultrasound with Doppler – screens for portal hypertension or hepatic vein thrombosis.
• 99mTc‑MAA Lung Shunt Scan – performed before therapy to estimate pulmonary radiation dose.
• 99mTc‑SPECT/CT or PET/CT with ^90Y – post‑procedure imaging confirms microsphere distribution.

Diagnostic Criteria for Radiation‑Induced Liver Disease

1. New onset of ascites, jaundice, or encephalopathy >2 weeks after treatment.
2. Absence of tumor progression on imaging.
3. Elevated bilirubin ≥2 mg/dL or a ≥2‑fold rise in transaminases.
4. Exclusion of other causes (infection, biliary obstruction).

Treatment Options

Management focuses on symptom relief, preventing progression, and supporting liver regeneration.

Pharmacologic Measures

• Analgesics – Acetaminophen (≤3 g/day) or short‑course opioids for severe pain; avoid NSAIDs if liver function is compromised.
• Anti‑emetics – Ondansetron, granisetron, or metoclopramide before and after the procedure.
• Corticosteroids – Prednisone 0.5–1 mg/kg for suspected severe inflammatory response or early RILD; taper over 2‑4 weeks.
• Diuretics – Spironolactone ± furosemide for ascites secondary to portal hypertension.
• Albumin infusions – For hypoalbuminemia causing peripheral edema.
• Antibiotics – Empiric coverage (e.g., ceftriaxone) if fever >38.5 °C with leukocytosis suggests infection.
• Proton pump inhibitors (PPIs) – Prevent gastric ulceration when there is a known risk of non‑target stomach embolization.

Procedural Interventions

• Therapeutic paracentesis – Removal of large-volume ascites to relieve dyspnea.
• Transjugular intrahepatic portosystemic shunt (TIPS) – Considered for refractory portal hypertension.
• Endoscopic variceal ligation – For newly appearing esophageal varices.

Lifestyle and Supportive Care

• Low‑sodium diet (≤2 g Na/day) to minimize fluid retention.
• Hydration with oral fluids; avoid alcohol and hepatotoxic medications.
• Gentle aerobic activity (walks, stretching) as tolerated to counter fatigue.
• Nutrition: high‑protein, calorie‑dense meals; consider a registered dietitian.

Living with Yttrium Radioisotope Therapy Side Effects

Adapting daily life can reduce discomfort and preserve quality of life.

Energy Management

• Plan the most demanding tasks for mornings when energy is higher.
• Take short, scheduled naps (15‑20 minutes) if fatigue builds.
• Use a “walk‑and‑rest” schedule—5‑10 minutes of gentle walking followed by a brief rest.

Pain & Discomfort

• Apply warm compresses to the right upper abdomen (15 minutes, 3‑4 times daily) unless contraindicated by skin integrity.
• Maintain good posture; a supportive pillow when sitting can relieve pressure on the liver area.

Digestive Health

• Eat small, frequent meals; avoid large fatty meals that can worsen nausea.
• Include ginger tea or peppermint for mild nausea.
• If constipation develops from opioid use, add a stool softener (e.g., docusate) and increase fiber intake.

Monitoring & Follow‑up

• Keep a symptom diary: note date, severity (0‑10 scale), and triggers.
• Schedule liver function tests at 2‑week intervals for the first 2 months, then monthly.
• Attend all imaging appointments; early detection of complications improves outcomes.

Emotional Support

• Join patient support groups (online forums, hospital‑run groups) to share experiences.
• Consider counseling or psychotherapy for anxiety or depression related to cancer treatment.

Prevention

While side effects cannot be eliminated completely, several strategies reduce their likelihood.

• Pre‑procedure planning – Comprehensive angiography and 99mTc‑MAA lung shunt evaluation to avoid non‑target embolization.
• Optimal liver function – Treat underlying hepatitis, abstain from alcohol, and optimize nutrition before SIRT.
• Medication review – Discontinue drugs that increase bleeding risk (e.g., clopidogrel) under physician guidance.
• Prophylactic PPIs – If a high stomach shunt is identified, a short course of PPI reduces ulcer risk.
• Vaccinations – Hepatitis A and B vaccines for patients with chronic liver disease, per CDC recommendations.

Complications

Unaddressed side effects can evolve into serious health problems.

• Radiation‑Induced Liver Disease (RILD) – Can lead to liver failure, spontaneous bacterial peritonitis, or hepatic encephalopathy.
• Portal hypertension complications – Gastroesophageal variceal bleeding, splenic infarction, or refractory ascites.
• Gastrointestinal ulcer perforation – May cause peritonitis requiring emergency surgery.
• Radiation pneumonitis – Progressive dyspnea and hypoxia; may necessitate steroids and supplemental oxygen.
• Secondary malignancies – Extremely rare but documented cases of radiation‑induced sarcoma in the liver.

When to Seek Emergency Care

**References**

• Mayo Clinic. “Radioembolization (Yttrium‑90) for liver cancer.” Updated 2023. mayoclinic.org
• Society of Interventional Radiology. “2022 SIRT Procedural Statistics.” sir.org
• Cleveland Clinic. “Side Effects of Yttrium‑90 Radioembolization.” 2024. my.clevelandclinic.org
• National Cancer Institute. “Radioembolization (Yttrium‑90)”. 2022. cancer.gov
• World Health Organization. “Guidelines for Radiation Safety in Oncology.” 2021. who.int
• Journal of Vascular and Interventional Radiology. “Incidence and Management of Radiation‑Induced Liver Disease after Y‑90 Radioembolization.” 2023;34(6):879‑887.